Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 13,555 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 13,555 shares of Bicara Therapeutics stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $18.22, for a total value of $246,972.10. Following the completion of the sale, the chief financial officer owned 145,355 shares in the company, valued at approximately $2,648,368.10. This represents a 8.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Ivan Hyep also recently made the following trade(s):

• On Wednesday, March 4th, Ivan Hyep sold 2,963 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.25, for a total transaction of $54,074.75.
• On Thursday, January 22nd, Ivan Hyep sold 1,882 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.15, for a total value of $34,158.30.

Bicara Therapeutics Stock Performance

Shares of BCAX stock traded down $0.04 during trading hours on Thursday, reaching $18.50. The company had a trading volume of 950,200 shares, compared to its average volume of 516,872. The business has a fifty day moving average price of $16.43 and a 200-day moving average price of $15.70. Bicara Therapeutics Inc. has a one year low of $7.80 and a one year high of $19.71.

Institutional Investors Weigh In On Bicara Therapeutics

Several institutional investors have recently added to or reduced their stakes in BCAX. Legal & General Group Plc increased its stake in Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after purchasing an additional 1,233 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Bicara Therapeutics by 73.0% during the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after purchasing an additional 1,474 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Bicara Therapeutics by 419.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after acquiring an additional 3,866 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Bicara Therapeutics during the fourth quarter worth about $45,000. Finally, Larson Financial Group LLC raised its stake in shares of Bicara Therapeutics by 1,015.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after buying an additional 3,595 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on BCAX. HC Wainwright restated a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Wedbush reiterated an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a report on Tuesday, January 13th. Mizuho upgraded shares of Bicara Therapeutics to a “hold” rating in a research note on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Friday, January 9th. Finally, UBS Group reissued a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Seven equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Bicara Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $28.33.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.